Epitope Editing Strategy Could Enable Less Toxic Stem Cell Transplants
Stem cell transplantation and gene therapy are among the most powerful curative approaches for blood diseases such as sickle cell disease, β-thalassemia, immune deficiencies, and some blood cancers. Replacing or correcting the blood-forming stem cells can offer the possibility of long-lasting benefit or a cure. However, before patients can receive these therapies, they usually need intensive and potentially toxic chemotherapy or radiation to clear space in the bone marrow for the new stem cells.
Global Food Safety Standards Body Codex Agrees On New Guidance On “May Contain” Allergen Labels
July 2026, Rome: The Codex Alimentarius Commission today agreed to adopt new international guidelines on the u…
Meet the 3 forces reshaping consumer palates and food industry profits
The profit structure for food and beverage companies is about to shift “on a scale that the food industry has not …
富美实意大利工厂完成唑草酮制剂首批生产，将用于荷兰市场
世界农化网中文网报道：近日，富美实公司（FMC）在其位于意大利San Colombano的生产基地完成了Spotlight® Plus 5L干燥剂（活性成分：唑草酮）的首批生产，该产品搭载了easyconnect™封闭式转移系统（CTS）。首批产品将用于在荷兰市场引入该技术。
Alchemab extends Series A with £25m from British Business Bank
Why it matters: The investment is the British Business Bank’s largest direct life sciences investment to date, and comes as the UK tries to keep more high-growth biotech companies scaling at home.
Fujifilm Selected with Six Others in FDA PreCheck Pilot Manufacturing Program
Fujifilm Biotechnologies reports that its commercial-scale cell culture manufacturing facility in Holly Springs, NC, has been selected as one of only seven participants in the FDA’s PreCheck Pilot Program. The program, which also includes Amneal Pharmaceutical, Cellares, Eli Lilly, Kriya Therapeutics, Kyowa Kirin, and Regeneron, is a strategic initiative designed to strengthen America’s pharmaceutical manufacturing capabilities and help accelerate patient access to critical medicines.
AZ buys ex-China rights to Sino’s COPD drug for $2.1bn
By the numbers: UK-based AstraZeneca is paying $200 million upfront plus $1.9 billion for the PDE 3/4 inhibitor TQC3721. The deal also includes tiered royalties ranging up to double-digit percentages based on the annual net sales of TQC3721 products.
科迪华提供原药、Crystal负责制剂开发与市场：双方共拓印度植保市场
世界农化网中文网报道：近日，Crystal Crop Protection Limited与科迪华签署合作协议，双方将在印度市场共同开发并商业化新型作物保护制剂和混配产品。根据协议，两家公司将合作进行产品开发、生产和商业化推广。
Olam Agri on what it takes to build self-reliant food systems across Africa
Africa has long been a part of the heritage and growth strategy for global agribusiness giant Olam Agri, which has opera…
定名″凌翘®″！泰禾首创化合物产品环丙氟虫胺开启全球化品牌新征程
世界农化网中文网报道： 南通泰禾化工股份有限公司正式官宣，其里程碑式自主创制化合物环丙氟虫胺确定专属中文商标——凌翘®。历经名称征集筛选、集团项目组全员票选等一系列流程，中文商标顺利完成注册并发布使用，标志着泰禾股份正式搭建起统一的全球化品牌体系，为自研产品出海、全球上市、长期品牌价值运营筑牢根基。